Assistant Professor, Pharmaceutical Sciences
Ph.D. (Pharmacology/Toxicology), University of Arizona, Tucson, AZ
M.S. (Toxicology), University of Arizona, Tucson, AZ
B.S. (Chemistry), University of Arizona, Tucson, AZ
Dr. Ham joined the faculty at Belmont University in the College of Pharmacy in 2012. Her primary teaching assignments are in the Pharmacodynamics series of classes. She also teaches electives in Toxicology and Pharmacogenomics & Personalized Medicine, as well as the third year Seminar class. She has a particular interest in increasing the knowledge of pharmacy students with respect to genetics/genomics (and related sciences) to prepare them the continually evolving field of pharmacogenomics and personalized medicine and their integration into pharmacy practice.
Prior to joining the faculty at Belmont, Dr. Ham was on faculty at Vanderbilt University School of Medicine (2003-2012) where her initial appointment was as a Research Assistant Professor of Biochemistry and an Associate Director of the Proteomics Laboratory in the Mass Spectrometry Research Center and was later appointed as a Research Associate Professor of Biochemistry and senior faculty in the Jim Ayers Institute for Precancer Detection and Diagnosis in the Vanderbilt Ingram Cancer Center. She maintains an adjunct appointment at Vanderbilt. Her research has primarily been collaborative in nature using proteomic and mass spectrometry approaches to study mechanisms of disease and for the discovery of biomarkers for detection, prognosis and treatment of various forms of cancers and other diseases. These collaborations have led to over 70 peer-reviewed publications. Her collaborators have ranged from cancer biologists and oncologists to experts in bioinformatics and analytical chemists.
Dr. Ham’s research interests include the use and further development of proteomic technologies and mass spectrometric approaches to enhance the discovery of protein biomarkers for personalized medicine. She is interested how protein biomarkers could be used to better understand the mechanisms by which drugs may produce their therapeutic effect and to distinguish subsets of disease that may require a more personalized therapeutic approach. Specifically, these biomarkers would be used to a) track therapeutic effectiveness or resistance of drugs through the understanding of their mechanistic therapeutic effect and b) find new molecular targets for the development of drugs for both new targeted therapies and co-therapies. She has a particular interest in using these technologies to study various forms of breast and colon cancer, primarily with respect to how drugs and resistance to drugs change the proteome, with a particular focus on tyrosine kinase inhibitor resistance. She is also interested in the role that protein post-translational modifications play in the disease process and their potential use as biomarkers.
View Dr. Ham's Curriculum Vitae
View Dr. Ham's Research Interests